Merck & Co., Inc. (NYSE:MRK) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks. Merck & Co., Inc. (NYSE:MRK) aims to make an entry into the weight loss drug market through the HS-10535 ...

Merck MRK announced that it has entered into a definitive agreement to acquire California-based cancer biotech, Terns ...

In the latest close session, Merck (MRK) was down 1.28% at $118.10. The stock trailed the S&P 500, which registered a daily loss of 0.4%. Elsewhere, the Dow saw an upswing of 0.11%, while the ...

Merck is bulking up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.

Some investors and analysts believe the pharma’s $6.7 billion offer is justified given Terns’ recent stock run. Others are ...

Merck & Co., Inc. (NYSE:MRK) is included among the Dividend Stock Portfolio for Income: 15 Stocks to Invest In. On March 25, ...

Merck & Co. agreed to buy Terns Pharmaceuticals Inc. for $6.7 billion, giving the multinational company access to a promising ...

Merck (NYSE: MRK) has taken its shareholders on a wild ride of late -- from last March's record high of more than $130 to this May's low near $76 back to its current price of just a little more than ...

Jim Cramer reviewed Merck & Co., Inc. (NYSE:MRK) while breaking down 16 stocks for a market facing higher energy costs and ...

Earlier this week, Merck & Co., Inc. reported detailed Phase 2 CADENCE results showing WINREVAIR (sotatercept-csrk) significantly reduced pulmonary vascular resistance in adults with combined post- ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: ...

Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the ...